Norigin Scientific

"Another War is coming.." - Dame Kate Bingham We at Norigin have been making major strides toward innovative advancements in combating anti-biotic resistant pathogens by pioneering new developments in anti-microbial coating technologies. Our coatings, applied in healthcare and various other mass density sectors, operate tirelessly to eradicate the most perilous pathogens round-the-clock, year after year. Our Company’s products testing sets the benchmark for comprehensive examination, ensuring unrivalled precision and reliability in assessing product efficacy and performance. Throughout our 4 year R&D programme rigorous and independent testing of our cutting-edge products have demonstrated exceptional efficacy against a diverse and dangerous spectrum of pathogens, these include but are not limited to: MRSA, E. Coli, C. difficile, Streptococcus pneumoniae, VRE, Pseudomonas Aeruginosa, CRE, and drug-resistant Campylobacter; as well as deadly fungal pathogens such as Candida Auris, Cryptococcus Neoformans, Candida Albicans, Candida Glabrata, and Penicillium Chrysogenum. Our commitment to ethical practices is as unwavering, as is our dedication to efficacy. We uphold the highest standard of safety and environmental responsibility. Our innovative approach aligns with this aim by integrating EPA AND EU BPR approved biocompatible biocides, This minimalist approach enables precise pathogenic elimination whilst reducing the likelihood of targeted pathogens developing AMR to our biocompatible microbicides whilst at the same time minimizing environmental impact. The global impact of Covid-19 has underscored that hospitals are not the only frontline in the fight against infection. High-density environments like residential, commercial and social settings, along with transportation hubs serve as fertile grounds for bacterial transmission. In light of this understanding that we are expanding our innovative solution to encompass these critical sectors.